Markus Hansson
31 – 40 of 73
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Bone marrow eosinophils in plasma cell disorders
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
- Contribution to journal › Article
-
Mark
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
- Contribution to journal › Article
- 2017
-
Mark
Identification of sequence variants influencing immunoglobulin levels
- Contribution to journal › Article
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
- Contribution to journal › Article
-
Mark
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- Contribution to journal › Article
-
Mark
NOX2-dependent immunosuppression in chronic myelomonocytic leukemia
- Contribution to journal › Article
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
- Contribution to journal › Article
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
- Contribution to journal › Article
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
- Contribution to journal › Article
